Social Medicines represents a logical next step in the evolution of the pharmaceutical system. Today, two dominant models exist: innovative pharma, optimized for blockbuster innovation at high prices, and generic pharma, focused on volume and marginal cost efficiency. Both models struggle to address the growing need for medicines for rare diseases, repurposed therapies, and personalized or precision medicine—where patient populations are small, development risk is asymmetric, and commercial incentives are misaligned.

Social Medicines was founded to fill this structural gap. We operate as a societal pharmaceutical company that collaborates with hospitals, academic institutions, and public partners to bring repurposed and neglected medicines to the EU market. By taking responsibility for regulatory development, manufacturing coordination, and market access, we enable therapies with proven scientific value to reach patients at fair, transparent prices.

Crucially, Social Medicines is not built around a single product, but as a scalable market-access platform. Our transparent, cost-based pricing model allows sustainable returns, while all proceeds are reinvested into a mission-locked fund for future development. This creates a flywheel: each successful registration funds the next, enabling a growing portfolio of essential medicines to reach patients.

By combining pharmaceutical execution with public-interest governance, Social Medicines drives systemic change—turning public research into sustained public access at scale.